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Serkan Demirci,*ac Asli Celebioglu,ab Zeynep Aytacab and Tamer Uyar*ab
Smart polymers and nanoﬁbers are potentially intriguing materials for controlled release of bioactive agents.
This work describes a new class of pH responsive nanoﬁbers for drug delivery systems with controlled
release properties. Initially, poly(4-vinylbenzoic acid-co-(ar-vinylbenzyl)trimethylammonium chloride)
[poly(VBA-co-VBTAC)] was synthesized via reversible addition–fragmentation chain transfer (RAFT)
polymerization. Then, ciproﬂoxacin was chosen as the model drug for the release study and encapsulated
into pH-responsive polymeric carriers of poly(VBA-co-VBTAC) nanoﬁbers via electrospinning. The
morphology of the electrospun nanoﬁbers was examined by scanning electron microscopy (SEM). The
structural characteristics of the pH responsive nanoﬁbers were investigated by Fourier transform infrared
spectroscopy (FTIR) and X-ray diﬀraction (XRD). The release measurements of ciproﬂoxacin from pH
responsive nanoﬁbers were also performed by high-performance liquid chromatography (HPLC) analysis.
To show the pH sensitivity of these nanoﬁbers, the release proﬁle of ciproﬂoxacin was examined under
acidic, neutral and basic conditions. The results indicate that pH responsive nanoﬁbers can serve as
eﬀective drug carriers since the release of ciproﬂoxacin could be controlled by changing the pH of the
environment, and therefore these drug loaded pH-responsive nanoﬁbers might have potential
applications in the biomedical ﬁeld.Introduction
Controlled drug release systems have gained much attention
in the last few decades and become an important topic in
medicine, due to various advantages such as improved ther-
apeutic eﬃcacy and reduced toxicity by delivering the drug at
controlled rates.1–3 Several synthetic and/or natural polymers
have been reported for controlled release studies.4–6 In
particular “smart” or “stimuli-responsive” polymers demon-
strated their potential as eﬀective carriers for controlled
release.7,8 The characteristic feature that makes them smart
is their ability to respond to the very slight changes in the
environment such as temperature, pH, electric eld, light or
magnetic eld.8–10 In addition, the morphological form of the
carrier matrix becomes a key factor aﬀecting the release
behavior. For instance, polymer based drug carriers can be
broadly classied into one of the following categories:
nanoparticles, nanogels, micelles, hydrogels and electrospun
nanobers, each with certain advantages and
disadvantages.11Center, Bilkent University, 06800 Ankara,
serkan.demirci@amasya.edu.tr; tamer@
nology, Bilkent University, 06800 Ankara,
and Sciences, Amasya University, 05100
056Electrospinning has become the most attractive nanober
production technique in the past decade due to its cost-eﬀec-
tiveness and versatility. This technique facilitates the produc-
tion of ultrane bers from a variety of materials such as
polymers (synthetic and/or natural), polymer blends, sol–gels,
composites, etc.12–14 In the electrospinning process, a contin-
uous lament is electrospun from polymer solutions or polymer
melts under a very high electrical eld, which resulted in
ultrane bers ranging from tens of nanometres to a few
microns in diameter. Such nanobrous structures have been
proposed for a number of applications due to their very high
surface-to-volume ratio with highly porous structures.12,13 The
morphology of electrospun nanobers can be controlled by
optimizing the factors such as electrospinning process param-
eters, the polymer solution, and environmental conditions.12,13
Further functionalizations of electrospun nanobers by phys-
ical/chemical post-treatments or incorporating active agents
during the electrospinning process are also quite feasible for
obtaining multifunctional nanobrous materials. Due to the
exclusive properties of electrospun nanobers and their nano-
brous webs, these are very promising candidates for
membranes/lters, biotechnology, textiles, sensors, energy,
electronics, and the environment.12–21 Especially, electrospun
nanobers can be ideal materials for drug delivery systems20–23
since encapsulation of drugs inside the nanober matrix can be
readily achieved by electrospinning where the target drug is
dissolved in the desired polymer solution. Numerous studiesThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinehave described the preparation of electrospun nanobers
containing pharmacologically active compounds and investi-
gated the release characteristics of drugs.22–29 Yet, the studies
dealing with the combination of pH responsive polymers and
nanobers for the drug delivery systems are very limited in the
literature.30
In this study, we developed pH-responsive poly(4-vinyl-
benzoic acid-co-(ar-vinylbenzyl)trimethylammonium chloride)
[poly(VBA-co-VBTAC)] nanobers for controlled drug release
study. Poly(VBA-co-VBTAC) was synthesized via reversible addi-
tion–fragmentation chain transfer (RAFT) polymerization and
pH responsive nanobers encapsulating ciprooxacin were
produced by electrospinning. The morphological, structural
and thermal characterization of the pH responsive nanobers
were performed by using scanning electron microscopy (SEM),
Fourier transform infrared (FTIR) and X-ray diﬀraction (XRD).
In order to investigate the pH responsive behavior, the release
prole of ciprooxacin from nanobers was examined under
acidic, neutral and basic conditions.Fig. 1 (a) Synthesis of poly(VBA-co-VBTAC). Schematic representation of
(b) electrospinning of ciproﬂoxacin encapsulated poly(VBA-co-VBTAC)
nanoﬁbers and (c) ciproﬂoxacin release from poly(VBA-co-VBTAC)/
ciproﬂoxacin nanoﬁbers.Materials and methods
Materials
(ar-Vinylbenzyl)trimethylammonium chloride (VBTAC, 99%,
Aldrich), 4,40-azobis(4-cyanopentanoic acid) (ACPA, $98%,
Aldrich), 4-cyano-4-(phenylcarbonothioylthio)pentanoic acid
(CPAD, 97%, Aldrich), ciprooxacin ($98%, Sigma-Aldrich),
potassium phosphate monobasic dihydrate ($98.0%, Sigma-
Aldrich), sodium phosphate monobasic dihydrate (Sigma-
Aldrich), sodium chloride (99.0–100.5%, Sigma-Aldrich),
sodium acetate trihydrate ($98.0%, Sigma-Aldrich), tris(hy-
droxymethyl)aminomethane ($98.8%, Sigma-Aldrich), N,N-
dimethylformamide (DMF, 99.8%, Sigma-Aldrich), acetone
($99.8%, Sigma-Aldrich) and acetic acid ($99.7%, Sigma-
Aldrich) were purchased commercially. ACPA was recrystallized
from methanol. 4-Vinylbenzoic acid (VBA) was prepared by a
standard method31 from a-bromo-p-toluic acid that was
synthesized according to a previously published protocol.32
Water was used from aMillipore Milli-Q ultrapure water system.RAFT-mediated polymerization procedure
RAFT-mediated polymerization of VBA (30.0 mmol) and VBTAC
(30.0 mmol) was performed with a 30 mL buﬀer solution (tris-
buﬀered saline, pH¼ 7.5), a free RAFT agent CPAD (0.3mmol) and
an initiator ACPA (0.06 mmol) at 0 C in a glass reactor. The
solution was diluted to a 100mL volumewith a buﬀer solution and
degassed by purging with nitrogen for 20 min. The polymerization
solution was heated slowly (approximately 30min) from 0 to 70 C.
The polymerization reaction solution (Fig. 1a) was stirred vigor-
ously at 70 C under a nitrogen atmosphere. Aer polymerization
reaction, poly(VBA-co-VBTAC), which was collected at the bottom
of the glass reactor, was ltered and dried at room temperature
under vacuum. The yield of poly(VBA-co-VBTAC) was determined
gravimetrically. The molecular weight distribution of the polymer
was measured by aqueous size exclusion chromatography (ASEC).This journal is © The Royal Society of Chemistry 2014Electrospinning
Firstly, a clear solution of poly(VBA-co-VBTAC) was prepared by
dissolving in a DMF–acetic acid (7/3) binary solvent mixture at
15% (w/v) polymer concentration. Then ciprooxacin was added
into polymer solution at 5% (w/w, according to polymer). The
ultimate ciprooxacin included and not-included polymer
solution was placed in a 3 mL syringe tted with a metallic
needle of 0.6 mm inner diameter. The syringe was xed
horizontally on the syringe pump (KDS 101, KD Scientic). The
electrode of a high-voltage power supply (Matsusada Precision,
AU Series) was clamped to the metal needle tip, and the
cylindrical aluminum collector was grounded (Fig. 1b). The
parameters of the electrospinning were adjusted as; feed rate of
solutions ¼ 1 mL h1, the applied voltage ¼ 15 kV, and the
tip-to-collector distance ¼ 10 cm. Electrospun nanobers were
deposited on a grounded stationary cylindrical metal collector
covered with a piece of aluminum foil. The electrospinning
apparatus was enclosed in a Plexiglas box, and electrospinning
was carried out at 25 C at 25% relative humidity. The collected
nanobers were dried at room temperature under a fume hood
overnight.
In vitro drug release studies
The release prole of ciprooxacin from pH responsive
nanobers was investigated via high performance liquid
chromatography (HPLC). A pH responsive nanobrous matPolym. Chem., 2014, 5, 2050–2056 | 2051
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View Article Onlineencapsulating ciprooxacin was immersed in 30 mL of
releasing media (acetate buﬀer solution, phosphate buﬀered
saline and tris-buﬀered saline) at 37 C for 720 minutes. 0.5 mL
aliquot was withdrawn at predetermined time intervals up to
720 minutes and in order to keep the volume constant, the
solution was replaced with the same volume of the fresh
medium each time an aliquot was taken out (Fig. 1c). To
determine the loading eﬃciency of ciprooxacin in nanobers,
a known weight of the sample was taken from three diﬀerent
parts of the nanobrous webs. These nanobers and a known
amount of ciprooxacin were dissolved in dimethylformamide–
acetic acid (7/3) solution. The solutions were stirred at room
temperature, 0.5 mL of aliquot was withdrawn and the total
amount of ciprooxacin was determined by HPLC by three
measurements. The HPLC results of nanobers were compared
with those of ciprooxacin powder solution.Fig. 2 The representative SEM images of (a) poly(VBA-co-VBTAC)
nanoﬁbers and (b) ﬁber diameter distribution; (c) poly(VBA-co-
VBTAC)/ciproﬂoxacin nanoﬁbers and (d) ﬁber diameter distribution;
photographs of poly(VBA-co-VBTAC) nanoﬁbrous mat (e) before and
(f) after swelling in deionized water.Measurements and characterization
The absolute molecular weights and dispersity of poly(VBA-co-
VBTAC) were determined by ASEC at ambient temperature
using Ultrahydrogel columns (120, 250, 500, and 1000 A˚;
Waters), a Wyatt Technology Optilab T-rEX RI detector
(l ¼ 690 nm), a Wyatt Technology Dawn Heleos II multiangle
laser light scattering detector (l ¼ 658 nm), and 1 wt% acetic
acid–0.1 M Na2SO4(aq.) as the eluent with a ow rate of 1.0 mL
min1. The dn/dc value of poly(VBA-co-VBTAC) (0.161 mL g1)
in the above eluent was determined at 25 C with a Wyatt
Technology Optilab T-rEX RI detector (l ¼ 690 nm). The
viscosity measurements of the electrospinning solutions were
performed with a rheometer (Physica MCR 301, Anton Paar)
equipped with a cone/plate accessory at a constant shear rate
of 100 s1 at 22 C. The morphology and the diameter of the
poly(VBA-co-VBTAC) and ciprooxacin-loaded poly(VBA-co-
VBTAC) [CIP-poly(VBA-co-VBTAC)] nanobers were examined
by using a scanning electron microscope (FE-SEM) (FEI,
Quanta 200 FEG). Samples were sputtered with 5 nm Au/Pd
(PECS-682) and around 100 ber diameters were measured
from the SEM images to calculate the average ber diameter of
each sample. The infrared spectra of the samples were
obtained by using a Fourier transform infrared spectrometer
(FTIR) (Bruker-VERTEX 70). The samples were mixed with
potassium bromide (KBr) and pressed as pellets. The scans
(64 scans) were recorded between 4000 and 400 cm1 at a
resolution of 4 cm1. The X-ray diﬀraction (XRD) (PANalytical
X'Pert Powder Diﬀractometer) patterns of nanobrous webs
and ciprooxacin powder were collected by using Cu Ka
radiation in a range of 2q ¼ 5–30. The released amount of
ciprooxacin from nanobers was determined by high
performance liquid chromatography (HPLC, Agilent, 1200
series) coupled with a VWD UV detector. The column was C18
(Agilent, particle size: 5 mm; column dimension: 150 mm  4.6
mm) operating at 0.5 mL min1. The mobile phase for sepa-
ration was 100% acetonitrile. The injection volume was 5 mL.
The UV detector was set at 217 nm. The experiments were
carried out in triplicate and the results were given as the
average  standard deviation.2052 | Polym. Chem., 2014, 5, 2050–2056Results and discussion
Preparation and characterization of pH responsive nanobers
Poly(VBA-co-VBTAC) with 52% VBA content33 was synthesized via
RAFT polymerization. We prepared copolymers with relatively
large molecular weights (approximately 32 000 g mol1, yield
86%, DI ¼ 1.08) to obtain uniform nanobers. The overall
procedure to prepare pH responsive nanobers is described in
Fig. 1. The morphological properties of the prepared nanobers
were observed using SEM (Fig. 2). SEM imaging showed that the
electrospun poly(VBA-co-VBTAC) nanobers and ciprooxacin
encapsulated poly(VBA-co-VBTAC) (poly(VBA-co-VBTAC)/cipro-
oxacin) nanobers were bead-free and have a smooth
morphology with an averageber diameter (AFD) of 310 65 and
445  120 nm, respectively. The poly(VBA-co-VBTAC)/cipro-
oxacin nanobers have higher ber diameter compared to
poly(VBA-co-VBTAC) nanobers because the viscosity of the
solution increased from 0.38 Pa$s to 0.59 Pa$s when ciprooxacin
was added into the polymer solution (Table 1). So, the electried
jet is subjected to less stretching during the electrospinning
process and thicker nanobers were obtained.12,34 Fig. 2 shows
the optical images of pH responsive nanobers before and aer
swelling in deionized water. The nanobers were initially opaque
and became translucent upon absorption of water.This journal is © The Royal Society of Chemistry 2014
Table 1 The characteristics of poly(VBA-co-VBTAC) and poly(VBA-co-VBTAC)/ciproﬂoxacin solutions and the resulting electrospun ﬁbers
Solutions
% Poly(VBA-co-VBTAC)
(w/v)
% Ciprooxacin
(w/v)
Viscosity
(Pa$s)
Fiber diameter
(nm) Fiber morphology
Poly(VBA-co-VBTAC) 15 — 0.38 310  65 Bead-free nanobers
Poly(VBA-co-VBTAC)/
ciprooxacin
15 5 0.59 445  120 Bead-free nanobers
Fig. 4 XRD patterns of ciproﬂoxacin, poly(VBA-co-VBTAC) nanoﬁbers
and poly(VBA-co-VBTAC)/ciproﬂoxacin nanoﬁbers.
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View Article OnlineFig. 3 shows the FTIR spectra of the ciprooxacin and the
electrospun nanobers. The characteristic band of cipro-
oxacin was observed at 1624 and 1272 cm1 due to the vibra-
tion of phenyl framework conjugated to –COOH and the
stretching vibration of the C–F bond, respectively. FTIR spectra
of ciprooxacin also showed an absorbance band at 3083 and
2918 cm1 for the C–H stretching from the phenyl ring.35,36 The
peaks at 1670, 1480 and 1409 cm1 were assigned to carbonyl
(C]O), scissor –CH2– vibration and asymmetric –CH3 defor-
mation vibration of the poly(VBA-co-VBTAC) nanobers,
respectively. Through the FTIR spectra of poly(VBA-co-VBTAC)/
ciprooxacin nanobers, it can be seen that absorption maxima
of stretching vibration shied toward lower wavenumbers
compared to the pure ciprooxacin and poly(VBA-co-VBTAC)
nanobers. All these results indicated that the model drug used
in this work had strong hydrogen bonds and ionic bonds with
the matrix of the poly(VBA-co-VBTAC) nanobers. At the same
time, there were no additional characteristic absorption bands
for drug-loaded poly(VBA-co-VBTAC)/ciprooxacin nanobers
elucidating that there was no noticeable chemical reaction
between the drug and the nanober matrix. This is an impor-
tant indication that ciprooxacin would keep its activity in the
poly(VBA-co-VBTAC)/ciprooxacin nanobrous matrix.
The X-ray diﬀraction (XRD) patterns of ciprooxacin and the
nanobrous mats of poly(VBA-co-VBTAC) and poly(VBA-co-
VBTAC)/ciprooxacin are depicted in Fig. 4. Ciprooxacin is aFig. 3 FTIR spectra of ciproﬂoxacin, poly(VBA-co-VBTAC) nanoﬁbers
and poly(VBA-co-VBTAC)/ciproﬂoxacin nanoﬁbers.
This journal is © The Royal Society of Chemistry 2014crystalline material having salient peaks centered at 2q ¼ 14,
21 and 25. Poly(VBA-co-VBTAC) is an amorphous polymer
showing a broad halo diﬀraction pattern. The absence of any
diﬀraction peak of crystalline ciprooxacin in the XRD pattern
of poly(VBA-co-VBTAC)/ciprooxacin nanobers indicated that
the ciprooxacin molecules were distributed in the nanobers
without forming any crystalline aggregates. Rashkov et al. have
reported crystal aggregates of ciprooxacin hydrochloride when
encapsulated in poly(L-lactide-co-D,L-lactide) (coPLA) or coPLA/
PEG electrospun nanobers, yet, in that study higher weight
load of drugs (10–30 wt%) was used, more importantly, cipro-
oxacin hydrochloride was not soluble in electrospinning
solution where a milky white suspension was obtained and
electrospun thereaer.37 In our case, the ciprooxacin was
soluble in the electrospinning solution forming a homogeneous
and clear solution with the polymer matrix. So, the rapid
evaporation of solvent during the electrospinning process
yielded amorphous dispersion of a crystalline drug in the
electrospun polymeric ber matrix as also reported for other
electrospun drug–polymer nanober systems.38,39 Moreover, inPolym. Chem., 2014, 5, 2050–2056 | 2053
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View Article Onlineour case, the hydrogen bonds between the drug molecules and
the polymer matrix possibly hindered the phase separation and
crystal aggregation of ciprooxacin throughout the poly(VBA-co-
VBTAC) matrix and therefore resulted in an amorphous phase.Fig. 6 The representative SEM images of poly(VBA-co-VBTAC)/
ciproﬂoxacin nanoﬁbers after release experiment; (a) acetate buﬀer
solution (pH ¼ 5.2), (b) phosphate buﬀered saline (pH ¼ 7.4) and (c)
tris-buﬀered saline (pH ¼ 8.8).Drug release from pH responsive nanobers
Ciprooxacin is a broad-spectrum uoroquinolone antibacte-
rial agent used in the treatment of both Gram-positive and
Gram-negative microorganisms. Ciprooxacin was chosen as a
model drug for investigating the pH responsive release ability of
electrospun poly(VBA-co-VBTAC) nanobers. The loading eﬃ-
ciency of nanobers loaded with 5% (w/w, with respect to
polymer) ciprooxacin was determined to be 93.4  3.4%. Fig. 5
shows the cumulative drug release (%) from poly(VBA-co-
VBTAC) pH responsive nanobers encapsulating ciprooxacin
into three diﬀerent release media having diﬀerent pH values;
acetate buﬀer solution (pH ¼ 5.2), phosphate buﬀered saline
(pH ¼ 7.4) and tris-buﬀered saline (pH ¼ 8.8). Two stages of
release can be distinguished in the release proles; aer a quick
initial release which continued for 30 minutes, the following
time interval showed sustained release of ciprooxacin from a
nanobrous matrix up to 240 minutes for acetate buﬀer solu-
tion and 480 minutes for phosphate buﬀered saline and tris-
buﬀered saline. No further drug release was observed aer 240
minutes into acetate buﬀer solution; whereas aer 480 minutes
no more drug was released into phosphate buﬀered saline and
tris-buﬀered saline.
It is a known fact that the release of a drug from a polymeric
matrix is mainly controlled by diﬀusion of the drug and/or
degradation of the matrix. The observed drug release was
attributed mainly to the diﬀusion or permeation of drug
through the polymer matrix. Since the time period of our
experiment (720 minutes) is not long enough to observe
degradation of polymer. In addition, as seen from the SEM
images of nanobers taken aer release experiment (Fig. 6), the
ber morphology of the poly(VBA-co-VBTAC) was retained aerFig. 5 Release proﬁles of ciproﬂoxacin from poly(VBA-co-VBTAC)/
ciproﬂoxacin nanoﬁbers in acetate buﬀer solution (pH ¼ 5.2), phos-
phate buﬀered saline (pH ¼ 7.4) and tris-buﬀered saline (pH ¼ 8.8).
2054 | Polym. Chem., 2014, 5, 2050–2056the release experiments were carried out in acetate buﬀer
solution, phosphate buﬀered saline and tris-buﬀered saline.
The release behaviors of drug are closely related to the
distribution of the drug within the matrix. Moreover, the solu-
bility and compatibility of the drug in the drug–polymer–solvent
system is of great importance in the release behavior of drugs
from polymeric nanobers. Therefore, when the drug is
hydrophilic and the polymer is hydrophobic or vice versa, and/or
the drug is not soluble in electrospinning solution, most of the
drug will be localized near the surface of nanobers due to the
phase separation and lack of the suﬃcient physical interaction
between the drug and the polymer matrix. This situation leads
to quite high initial burst release.40,41 However, in our case both
ciprooxacin and poly(VBA-co-VBTAC) are hydrophobic, so they
are compatible; and ciprooxacin is soluble in DMF–acetic acid
(7/3) solution. Therefore, initial burst release was not so high.
This may be due to the increasing intermolecular and/or
intramolecular interactions. An initial burst release is required
for the delivery of antibiotic drugs aiming to prevent bacterial
proliferation at the initial stage; whereas, for a few organisms
that manage to survive, sustained release is also needed for
antibiotics.41 Here, the sustained release of ciprooxacin was
observed as well. The total release amount of ciprooxacin from
nanobers was more in acetate buﬀer solution compared to
phosphate buﬀer saline and tris-buﬀered saline. The poly(VBA-
co-VBTAC) includes cationic VBTAC units and pH-responsive
VBA units. This might be due to the weak electrostatic interac-
tion between VBA and VBTAC units at lower pHs which are
below the pKa. In our previous study, we showed that the pKa of
poly(VBA-co-VBTAC) polymer brushes on silicon wafer surfaces
was 7.65.33 On the other hand, Gabaston et al. and Liu and
Armes reported that the pKa value of VBA homopolymer was 4.4
and 7.1, respectively.42,43 The total release amount of cipro-
oxacin from nanobers was decreased with increasing pH,This journal is © The Royal Society of Chemistry 2014
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View Article Onlinebecause of the increasing electrostatic interactions. The
remaining ciprooxacin content in nanobers may originate
from this interaction as well. In brief, our electrospun poly(VBA-
co-VBTAC) nanobers encapsulating ciprooxacin could
present a rapid enough release for bacteria not to proliferate at
rst stage but could provide a sustained release as well owing to
the diﬀusionmechanism dominating in release of ciprooxacin
from nanobers.
Conclusions
In conclusion, pH-responsive poly(VBA-co-VBTAC) nanobers
encapsulating ciprooxacin were successfully prepared via
electrospinning techniques for the purpose of controlled drug
release systems. SEM imaging proved that the electrospinning
of nanobers from poly(VBA-co-VBTAC) was successful and
encapsulation of ciprooxacin did not aﬀect the morphology of
the nanobers where a bead-free and smooth ber morphology
was observed for both poly(VBA-co-VBTAC) and poly(VBA-co-
VBTAC)/ciprooxacin nanobers. The presence of ciprooxacin
in the poly(VBA-co-VBTAC) nanobers was conrmed by FTIR
spectroscopy. XRD data suggested that ciprooxacin was
homogeneously distributed within the poly(VBA-co-VBTAC)
nanobers without forming phase separated crystalline aggre-
gates. Results of in vitro release experiments suggested that the
poly(VBA-co-VBTAC)/ciprooxacin nanobers were capable of
eﬀectively delivering ciprooxacin in a controlled fashion with
prolonged duration depending on the pH. The initial burst
release was higher with increasing pH values, because of the
increasing intermolecular and/or intramolecular interactions.
However, the total release amount of ciprooxacin from nano-
bers was more in acetate buﬀer solution compared to higher
pH values. This pH-responsive poly(VBA-co-VBTAC) nanobers
may provide opportunities to develop innovative responsive
materials for various applications. For instance, our newly
developed pH responsive nanobers may be potentially useful
for controlled drug delivery and biomedical engineering.
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